The approaches that many pharmaceutical companies are using to advance patient loyalty and adherence provide opportunities for optimization. These strategies are typically short-term and fail to appreciate the complex and personal issues surrounding a patient's individual barriers to compliance and persistency. There is a significant growing need for companies to move beyond addressing just the well-defined financial barriers. It is therefore now vital to create a more customized, patient-centric relationship program that will provide them with targeted interventions to forge patient relationships that will lead to better, longer-term adherence and health outcomes.
Click Here to join Frost & Sullivan, along with our distinguished panel of industry experts, as we take a look at the changing dynamics in today's U.S. pharmaceutical industry. We'll review traditional adherence programs, examine what is and is not working and what the next steps are toward addressing the multiple barriers contributing to non-adherence.
Derek S. Rago, Director of Relationship Marketing, McKesson Specialty
As pharmaceutical brand managers continue the daunting task of encouraging patients to stay on their prescription regimens...
Denton Chase, President, Chodon LLC.This case study will go through an actual patient support program that was developed for a brand in a niche disease. The case...
RETURN TO: Home > Our Services > Events
RETURN TO: Home > Our Services > Events 
